By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study evaluating its investigational drug HRS9531 in adult patients with type 2 diabetes (T2D) who have poor blood glucose control despite basic insulin treatment.
HRS9531: Dual Receptor Agonist
HRS9531 is a novel dual gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 (GLP-1) receptor agonist. The drug has previously been approved for clinical study in China for weight management and obstructive sleep apnea combined with obesity. This new approval expands its potential therapeutic applications to include glycemic control in T2D patients.-Fineline Info & Tech